P2RY1 and COVID-19: The RECOVERY, ACTIV-4a and REMAP-CAP trials evaluated the effects of aspirin or P2Y12 ADP-receptor antagonists in hospitalised patients admitted with mild to severe COVID-19 [26, 33, 34].